Group 1 - The core viewpoint of the article indicates that Kangyuan Pharmaceutical has experienced a significant decline in both revenue and net profit for the third quarter and the first three quarters of the year [1] Group 2 - In the third quarter, the company's revenue was 701 million yuan, representing a year-on-year decrease of 17.42% [1] - The net profit for the third quarter was 57.27 million yuan, down 20.88% year-on-year [1] - For the first three quarters, the total revenue amounted to 2.343 billion yuan, reflecting a year-on-year decline of 24.59% [1] - The net profit for the first three quarters was 200 million yuan, which is a decrease of 35.63% compared to the same period last year [1]

证券简称：康缘药业 证券代码：600557 公告编号：2025-033 江苏康缘药业股份有限公司（以下简称"公司"）全资子公司江苏中新医药有限 公司（以下简称"中新医药"）近日收到国家药品监督管理局签发的关于 ZX2021 注 射液新增用于治疗代谢功能障碍相关脂肪性肝病适应症的《药物临床试验批准通知 书》。按照《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》的相关 要求，现将相关情况公告如下： 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月 14 日受理的 ZX2021 注射液临床试验申请符合药品注册的有关要求，同意本品开 展临床试验，申请的适应症为代谢功能障碍相关脂肪性肝病。 提交的临床试验方案名称：评估 ZX2021 注射液治疗代谢功能障碍相关脂肪性肝 病有效性和安全性的随机、双盲、安慰剂对照、剂量递增 II 期临床研究。 二、药品研发及相关情况 药品名称 ZX2021 注射液 注册分类 治疗用生物制品 1 类 原适应症 超重或肥胖、2 型糖尿病 增加适应症 代谢功能障碍相关脂肪性肝病 剂型 注射剂 申请人 江苏中新医药有限公司 受理号 CXSL25006 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 截至本公告披露日，持股 5%以上股东连云港康贝尔医疗器械有限公司（以下简 称"康贝尔"）持有江苏康缘药业股份有限公司（以下简称"公司"）31,870,567 股 无限售流通股股份，占公司总股本比例 5.63%；本次股份解除质押业务办理完成后， 康贝尔剩余累计质押的本公司股份数量为 7,000,000 股，占其持有公司股份的 21.96%，占公司总股本的 1.24%。 证券简称：康缘药业 证券代码：600557 公告编号：2025-032 江苏康缘药业股份有限公司 关于持股 5%以上股东部分股份解除质押的公告 近日，公司接到持股 5%以上股东康贝尔的通知，康贝尔将其所持有的公司部分 股份办理了解除质押，相关手续已办理完毕。具体情况如下： | 股东名称 | 连云港康贝尔医疗器械有限公司 | | | --- | --- | --- | | 本次解除质押股份 | 24,870,000 | 股 | | 占其所持股份比例 | 78.03% | | | 占公司总股本比例 ...

Core Viewpoint - Kangyuan Pharmaceutical's wholly-owned subsidiary, Jiangsu Zhongxin Pharmaceutical Co., Ltd., has received a clinical trial approval notice from the National Medical Products Administration for ZX2021 injection to treat metabolic dysfunction-related fatty liver disease [1] Group 1 - The approval signifies a potential expansion of ZX2021's therapeutic applications, which may enhance the company's product portfolio and market competitiveness [1] - This development aligns with the growing focus on metabolic diseases in the pharmaceutical industry, indicating a strategic move by the company to tap into this emerging market [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.34% on October 23, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Notable gainers included: - Qidi Pharmaceutical (Code: 000590) with a closing price of 12.68, up 9.97% and a trading volume of 261,000 shares, totaling 320 million yuan [1] - Zhendong Pharmaceutical (Code: 300158) closed at 7.32, up 4.27% with a trading volume of 1,012,600 shares, totaling 753 million yuan [1] - Major decliners included: - Zhongsheng Pharmaceutical (Code: 002317) closed at 18.43, down 4.75% with a trading volume of 569,600 shares, totaling 1.056 billion yuan [2] - Darentang (Code: 600329) closed at 43.15, down 3.68% with a trading volume of 75,800 shares, totaling 328 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 897 million yuan from institutional investors, while retail investors contributed a net inflow of 989 million yuan [2] - The table of capital flow indicates that: - Qidi Pharmaceutical had a net inflow of 23.93 million yuan from institutional investors, while retail investors had a net outflow of 25.84 million yuan [3] - Zhendong Pharmaceutical experienced a net inflow of 19.97 million yuan from institutional investors, with retail investors seeing a net outflow of 2.25 million yuan [3]

Core Viewpoint - On October 9, a total of 11 listed companies had their restricted shares unlocked, with a total market value of approximately 24.303 billion yuan [1] Summary by Category Restricted Share Unlocking - The companies involved in the unlocking of restricted shares include: - Guo Xin Health (000503) with 1.6798 million shares from equity incentive restrictions - Kang Yuan Pharmaceutical (600557) with 315,500 shares from equity incentive restrictions - Sen Te Co., Ltd. (603098) with 270,000 shares from equity incentive restrictions - San Ren Xing (605168) with 165,300 shares from equity incentive restrictions - Hai Liang Data (603138) with 5.6629 million shares from equity incentive restrictions - Tian Yi Medical (301097) with 40.6 million shares from extended lock-up period - Ming Li Da (301268) with 19 million shares from extended lock-up period - Heng Yu Xintong (300965) with 3.51045 million shares from extended lock-up period - Pu Yuan Jing Dian (688337) with 11.8 million shares unlocked - Zhong Fu Shen Ying (688295) with 29.8 million shares unlocked - Chang Guang Hua Xin (688048) with 7.007 million shares unlocked [1]

Summary of Key Points Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. announced that its major shareholder, Lianyungang Kangber Medical Equipment Co., Ltd., has pledged part of its shares, which may indicate potential liquidity issues or strategic financial maneuvers [1]. Group 1: Shareholding and Pledge Details - Lianyungang Kangber holds 31,870,567 shares of Jiangsu Kangyuan, representing 5.6293% of the total share capital [1]. - After pledging 7 million shares, Kangber has cumulatively pledged 31.87 million shares, which accounts for 99.9982% of its holdings and 5.6292% of the company's total share capital [1]. Group 2: Pledge Usage - The pledged shares are not being used as collateral for major asset restructuring performance compensation or other guarantees [1].

Group 1 - The core point of the article is that Kangyuan Pharmaceutical announced that its major shareholder, Lianyungang Kangbeier Medical Equipment Co., Ltd., has pledged part of its shares, specifically 7 million shares [2] Group 2 - The announcement was made on the evening of September 26 [2] - The shareholder involved holds more than 5% of the company's shares [2]

Group 1 - The core point of the news is that Kangyuan Pharmaceutical has announced a significant share pledge by its subsidiary, Kangbei Medical Equipment, which has pledged 7 million shares, bringing the total pledged shares to 31,870,567, representing 5.6293% of the company's total equity [1] - As of the announcement date, Kangbei has pledged a total of 31,870,000 shares, which accounts for approximately 100% of its holdings in the company [1] - Kangyuan Pharmaceutical's market capitalization is reported to be 8.5 billion yuan [2]

连云港康贝尔医疗器械有限公司（以下简称"康贝尔"）持有江苏康缘药业 股份有限公司（以下简称"公司"）股票 31,870,567 股，占公司总股本的 5.6293%。 本次质押 700 万股后，康贝尔累计质押公司股份 3,187 万股，占其持股数量比例为 99.9982%，占公司总股本比例为 5.6292%。 证券简称：康缘药业 证券代码：600557 公告编号：2025-031 江苏康缘药业股份有限公司 关于持股 5%以上股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司于近日收到持股 5%以上股东康贝尔通知，康贝尔将其持有的本公司部分 股票进行质押，现将相关情况公告如下： 一、本次股份质押基本情况 1、本次股份质押基本情况 | 合计 | | | 尔 | 康贝 | | | 名称 | 股东 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | / | | | | 否 | | | 东 | 控股 ...